Bley Carla Rohrer, Jochum Wolfram, Orlowski Katrin, Furmanova Polina, Vuong Van, McSheehy Paul M J, Pruschy Martin
Department of Radiation Oncology, University Hospital Zurich, Section of Radio-Oncology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Clin Cancer Res. 2009 Feb 15;15(4):1335-42. doi: 10.1158/1078-0432.CCR-08-0969.
The combined treatment modality of ionizing radiation (IR) and the clinically relevant microtubule-stabilizing compound patupilone (epothilone B, EPO906) is a promising approach for anticancer therapy. Here, we investigated the role of the tumor microenvironment for the supra-additive in vivo response in tumor xenografts derived from patupilone-sensitive and patupilone-resistant non-small cell lung cancer cells.
The treatment response to a combined regimen of patupilone and IR was investigated in vitro and in tumor xenografts derived from wild-type A549 and A549.EpoB40 cells, which are resistant to patupilone due to a beta-tubulin mutation.
In both A549 and A549.EpoB40 cells, proliferative activity and clonogenicity were reduced in response to IR, whereas patupilone, as expected, inhibited proliferation of the mutant cell line with reduced potency. Combined treatment with patupilone and IR induced a cytotoxic effect in vitro in an additive way in A549 cells but not in the tubulin-mutated, patupilone-resistant A549.EpoB40 cells. A supra-additive tumor growth delay was induced by combined treatment in xenografts derived from A549 cells but not in xenografts derived from A549.EpoB40 cells. Histologic analysis revealed a significant decrease in tumor cell proliferation (Ki-67) and microvessel density and a treatment-dependent change of tumor hypoxia in A549 but not A549.EpoB40 xenografts.
Using a genetically defined patupilone-sensitive and patupilone-resistant tumor model, we here showed that the major cytotoxic effect of the combined treatment modality of IR and patupilone is directed against the tumor cell compartment. The induced antiangiogenic effect derives indirectly from the tumor cell.
电离辐射(IR)与临床相关的微管稳定化合物帕土匹龙(埃坡霉素B,EPO906)联合治疗模式是一种很有前景的抗癌治疗方法。在此,我们研究了肿瘤微环境在源自对帕土匹龙敏感和耐药的非小细胞肺癌细胞的肿瘤异种移植体内超加成反应中的作用。
在体外以及源自野生型A549和A549.EpoB40细胞的肿瘤异种移植中研究了帕土匹龙与IR联合方案的治疗反应,A549.EpoB40细胞由于β-微管蛋白突变而对帕土匹龙耐药。
在A549和A549.EpoB40细胞中,增殖活性和克隆形成能力均因IR而降低,而正如预期的那样,帕土匹龙抑制了突变细胞系的增殖,但其效力有所降低。帕土匹龙与IR联合治疗在体外对A549细胞以加成方式诱导细胞毒性作用,但对微管蛋白突变的、对帕土匹龙耐药的A549.EpoB40细胞则无此作用。联合治疗在源自A549细胞的异种移植中诱导了超加成的肿瘤生长延迟,但在源自A549.EpoB40细胞的异种移植中则未诱导。组织学分析显示,A549异种移植而非A549.EpoB40异种移植中的肿瘤细胞增殖(Ki-67)和微血管密度显著降低,且肿瘤缺氧情况有治疗依赖性变化。
使用基因定义的对帕土匹龙敏感和耐药的肿瘤模型,我们在此表明,IR与帕土匹龙联合治疗模式的主要细胞毒性作用针对肿瘤细胞区室。诱导的抗血管生成作用间接源自肿瘤细胞。